Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02483104
• Other study ID #: M14-488
• Status: Completed
• Phase: Phase 1
• First received: June 24, 2015
• Last updated: November 16, 2017
• Start date: July 2015
• Est. completion date: July 2016

Study information

• Verified date: August 2016
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: July 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 99 Years

Eligibility

Inclusion Criteria:

Histologically or cytologically confirmed epithelial ovarian, fallopian tube or primary peritoneal carcinoma the International Federation of Gynecology and Obstetrics (FIGO) Stage IC - IV with either optimal (< 1 cm residual disease) or suboptimal residual disease.

Participants must be newly diagnosed, chemotherapy-naïve, and entered between 1 and 12 weeks after initial cytoreductive surgery.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

Adequate organ and marrow function.

Ability to swallow and retain oral medication, and no uncontrolled emesis.

Women of childbearing potential (except vasectomized partner of female subjects) must agree to use adequate contraception prior to study entry, for the duration of study participation and up to 3 months following completion of therapy. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the study entry. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

Exclusion Criteria:

A history of another invasive cancer within the past 3 years, except non-melanoma skin cancer or in situ malignancies that are considered cured by the investigator (e.g., cervical cancer in situ, in situ carcinoma of the bladder, or breast carcinoma in situ).

Participants who received prior radiotherapy to any portion of the abdominal cavity or pelvis.

Participants who received prior chemotherapy for any abdominal or pelvic tumor.

Any investigational agents less than 4 weeks prior to study enrollment.

Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study enrollment.

Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.

Patients with history or evidence upon physical examination of central nervous system disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of the first date of treatment on this study.

Prior therapy with a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.

Subject has a clinically significant uncontrolled condition(s), including but not limited to:

• Uncontrolled seizure disorder, or focal or generalized seizure within the last 12 months;

• Active infection that requires parenteral antibiotics;

• Known active hepatitis B or hepatitis C with abnormal liver function test or organ dysfunction;

• Symptomatic congestive heart failure; unstable angina pectoris; serious ventricular cardiac arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication (this does not include asymptomatic atrial fibrillation with controlled ventricular rate); or myocardial infarction within the last 6 months;

• Uncontrolled hypertension (sustained systolic blood pressure > 150 mmHg or diastolic pressure > 100 mmHg despite optimal medical management);

• Bowel obstruction or gastric outlet obstruction;

• Psychiatric illness/social situations that would limit compliance with study requirements;

• Any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicities.

Pregnant or lactating.

Related Conditions & MeSH terms

• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• veliparib
Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
• carboplatin
Carboplatin will be administered on Day 1 of each cycle, intravenously.
• paclitaxel
Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.

Locations

Country	Name	City	State
Japan	Site Reference ID/Investigator# 128815	Kurume-shi,Fukuoka
Japan	Site Reference ID/Investigator# 128997	Morioka-shi
Japan	Site Reference ID/Investigator# 128058	Nagaizumi-cho

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, Kiriyama T, Komarnitsky P, Hirashima Y, Ushijima K. Phase 1 study of veliparib with carboplatin a — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Dose-limiting toxicities		During the first cycle (21 days) of veliparib administration
Secondary	Number of participants with adverse events	Collect all adverse events at each visit and assess according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03	Approximately 5 months
Secondary	Preliminary tumor response	According to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1	Participants will be evaluated for 5 months.
Secondary	Maximum observed plasma concentration (Cmax) of Veliparib	Maximum observed concentration, occurring at Tmax	For 24 hours following veliparib dosing.
Secondary	The time to Cmax (peak time, Tmax) of Veliparib	The time at which maximum plasma concentration (Cmax) is observed.	For 24 hours following veliparib dosing.
Secondary	The area under the plasma concentration-time curve (AUC) of Veliparib		For 24 hours following veliparib dosing.